Table 1.
Clinicopathologic characteristics and outcome of patients with upper tract urothelial carcinoma.
| Variable | Immunohistochemical Analysis | RNA Sequencing Analysis |
|---|---|---|
| n = 99 | n = 72 | |
| Age (year), median (range) | 71 (48–87) | 73 (45–89) |
| Sex, n (%) | ||
| Male | 60 (60.6) | 55 (76.4) |
| Female | 39 (39.4) | 17 (23.6) |
| Laterality, n (%) | ||
| Right | 43 (43.4) | 38 (52.8) |
| Left | 56 (56.6) | 34 (47.2) |
| Tumor location, n (%) | ||
| Renal pelvis | 45 (45.5) | 27 (37.5) |
| Ureter | 50 (50.5) | 43 (59.7) |
| Both | 4 (4.0) | 2 (2.8) |
| Tumor grade, n (%) | ||
| Low-grade | 15 (15.2) | 8 (11.1) |
| High-grade | 84 (85.9) | 64 (88.9) |
| Pathological T stage, n (%) | ||
| pTa | 19 (19.2) | 14 (19.4) |
| pT1 | 18 (18.2) | 22 (30.6) |
| pT2 | 8 (8.1) | 10 (13.9) |
| pT3 | 48 (48.5) | 23 (31.9) |
| pT4 | 6 (6.1) | 3 (4.2) |
| Lymphovascular invasion, n (%) | ||
| Yes | 40 (40.4) | 50 (69.4) |
| No | 59 (59.6) | 22 (30.6) |
| Lymph node metastasis, n (%) | ||
| pN0 | 84 (84.8) | 63 (87.5) |
| pN+ | 12 (12.1) | 9 (12.5) |
| pNx | 3 (3.0) | 0 (0.0) |
| High-risk group †, n (%) | ||
| Yes | 60 (60.6) | 33 (45.8) |
| No | 36 (36.4) | 39 (54.2) |
| Unknown | 3 (3.0) | 0 (0.0) |
| Adjuvant chemotherapy, n (%) | ||
| Yes | 26 (26.3) | 12 (16.7) |
| No | 63 (63.6) | 60 (83.3) |
| Progression, n (%) | ||
| Yes | 38 (38.4) | 25 (34.7) |
| No | 61 (61.6) | 47 (65.2) |
| Follow-up (month), median (range) | 37 (1–173) | 28 (2–88) |
† High-risk group is defined as patients with a pathologic stage of ≥pT3 or positive lymphatic invasion or lymph node metastasis.